Superluminal Medicines ACCELERATING NEW POSSIBILITIES IN DRUG DISCOVERY AND DEVELOPMENT

Superluminal Medicines, a biotechnology company integrating AI/ML, protein dynamics and structural biology to rapidly unlock some of the most challenging G protein-coupled receptor (GPCR) targets, today announced the closing of an oversubscribed $60 million Series B financing. Proceeds will support advancing Superluminal’s lead program for rare genetic forms of obesity and hypothalamic obesity, expected to begin by the end of 2026. 

BVF Partners, L.P., led the financing, with participation from new investors Deep Track Capital and Perceptive Advisors, along with existing investors RA Capital Management, Insight Partners, NVentures (NVIDIA’s venture capital arm), Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels.

 

Superluminal is eligible to receive up to $1.3 billion, which includes upfront and near-term payments, an equity investment, development and commercial milestones, as well as tiered royalties on net sales.